Abuse Potential of Buprenorphine/Naloxone

Stopped early · Phase 2

Conditions studied: Opioid-Related Disorders

In brief

Buprenorphine is a treatment for opioid dependence. Naloxone is given in addition to buprenorphine in order to limit the abuse potential that is commonly associated with buprenorphine. The purpose of this study is to determine the abuse potential of high doses of buprenorphine/naloxone in opioid dependent individuals.

Key facts

Study ID

NCT00149539

Run by

National Institute on Drug Abuse (NIDA)

People needed

12

Starts

2004-06-01

Expected to finish

2006-01-01

Last updated by the study team

2017-01-12

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Actively abusing illegal opioids
• Qualifies for opioid substitution treatment (e.g., methadone or buprenorphine), but not in active treatment at the time of study entry
• Meets DSM-IV criteria for opioid dependence

You may not qualify if…

• Significant medical problems (e.g., insulin dependent diabetes mellitus)
• Non-substance use psychiatric disorders (e.g., schizophrenia)
• Seeking substance abuse treatment

Where it is running

• Johns Hopkins University (BPRU) Bayview Campus — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.